Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AusBiotech Special: Australia's Place in the Global Gravity Shift (Australia)

This article was originally published in PharmAsia News

Executive Summary

According to figures compiled by PricewaterhouseCoopers (PwC), the Australian biotech industry is currently worth more than $30 billion. The majority of that revenue comes from the country's three leading companies, CSL, Cochlear, and Resmed. Experts predict the market will continue to grow by about 10 percent each year for the next three years. To encourage further growth, Australian companies need to be aware of the shifting balance in the pharmaceutical and biotechnology fields. Over the next few years, Asian countries are expected to take the reigns from the United States and Europe when it comes to both production and demand for medications. A PwC survey found that 55 percent of international companies and 62 percent of domestic companies project Asia will become the center of the global pharmaceutical market. In preparation for this shift, experts recommend Australian biotech companies form alliances with Asian entities, especially those based in China, Japan, India, and Singapore. (Click here for more - May Require Paid Subscription

You may also be interested in...

CV Sciences Reboots PlusCBD Brand While Counting On New Immunity Products During Flu Season

CV Defense, the second launch in the firm’s new immune-support line (without cannabidiol), is built around palmitoylethanolamide and other nutrients and botanicals to “optimize immune response.” CV Sciences touts the immunity range as complementary to its PlusCBD brand, which is in the process of rolling out dozens of new products in updated packaging.

Finance Watch: Have Investors Reached IPO Fatigue?

Public Company Edition: Codiak, Kiromic, Aligos and Opthea have fallen below their initial public offering values, while Tarsus and Praxis are trading higher. Also, 5AM, MPM and Cormorant took biotech SPACs public and Evotec led recent non-IPO financings with a €250m private placement.

Expediting The Expedited: How Rolling CMC Review Process Is Working For COVID-19 Vaccines

US, EU and Canadian authorities recently discussed their approaches to rolling reviews of CMC applications for coronavirus vaccines.





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts